Edition:
United States

TG Therapeutics Inc (TGTX.OQ)

TGTX.OQ on NASDAQ Stock Exchange Capital Market

11.80USD
21 Sep 2017
Change (% chg)

-- (--)
Prev Close
$11.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
346,696
52-wk High
$15.35
52-wk Low
$4.10

Latest Key Developments (Source: Significant Developments)

TG Therapeutics says phase 3 ULTIMATE trials evaluating TG-1101 in multiple sclerosis patients are now open for enrollment
Friday, 15 Sep 2017 07:30am EDT 

Sept 15 (Reuters) - TG Therapeutics Inc :TG Therapeutics Inc announces the phase 3 ultimate trials evaluating tg-1101 in patients with multiple sclerosis are now open for enrollment.TG Therapeutics Inc - ‍ ULTIMATE I and ULTIMATE II phase 3 trials will each enroll approximately 440 subjects, randomized in a 1:1 ratio.  Full Article

TG Therapeutics announces completion of target enrollment
Tuesday, 5 Sep 2017 07:30am EDT 

Sept 5 (Reuters) - TG Therapeutics Inc ::TG Therapeutics announces completion of target enrollment in the unity-CLL phase 3 trial.TG Therapeutics Inc - ‍unity-CLL phase 3 trial is being conducted pursuant to a special protocol assessment (SPA) agreement with FDA.TG Therapeutics Inc - ‍enrollment is expected to continue until mid-October​.TG Therapeutics Inc- expect to deliver top-line data on ORR endpoint earlier than anticipated, now expected in Q2 of 2018.  Full Article

TG Therapeutics announces successful outcome from first pre-planned interim analysis
Thursday, 10 Aug 2017 07:30am EDT 

Aug 10 (Reuters) - TG Therapeutics Inc :TG Therapeutics Inc announces successful outcome from the first pre-planned interim analysis by independent DSMB of the DLBCL cohort in the unity-NHL PHASE 2B trial.TG Therapeutics Inc - ‍DSMB recommends continued enrollment in TGR-1202 + TG-1101 arm and no further enrollment into single agent TGR-1202 arm​.TG Therapeutics Inc - ‍single agent TGR-1202 arm will be replaced with triple combination of TG-1101, TGR-1202 and bendamustine​.  Full Article

TG Therapeutics Q2 loss per share ‍$0.45​
Wednesday, 9 Aug 2017 07:30am EDT 

Aug 9 (Reuters) - Tg Therapeutics Inc :Tg therapeutics Inc provides business update and reports second quarter 2017 financial results.Qtrly loss per share ‍$0.45​.Expect G&A expenses to remain relatively constant through remainder of 2017​.  Full Article

TG therapeutics provides FDA update on multiple sclerosis study
Tuesday, 1 Aug 2017 07:30am EDT 

Aug 1 (Reuters) - Tg Therapeutics Inc :Announces special protocol assessment (spa) agreement with the FDA for a Phase 3 program of TG-1101 (ublituximab) for patients with multiple sclerosis (MS).Global Phase 3 program expected to commence before end of Q3 2017.RMS phase 3 program consists of two trials, called Ultimate I and Ultimate II trials.  Full Article

TG Therapeutics gives follow-up data from chemo-free triple combination
Monday, 5 Jun 2017 09:00am EDT 

June 5 (Reuters) - TG Therapeutics Inc :TG Therapeutics Inc Announces follow-up data from the chemo-free triple combination of TG-1101, TGR-1202, and Ibrutinib at the 53rd annual meeting of the American Society Of Clinical Oncology.TG Therapeutics Inc - ‍ triple combination appeared to be well tolerated in all patients, with neutropenia and pneumonia​‍​.  Full Article

TG Therapeutics files for potential mixed shelf offering of up to $300 mln
Friday, 26 May 2017 04:49pm EDT 

May 26 (Reuters) - TG Therapeutics Inc ::TG Therapeutics inc files for potential mixed shelf offering of up to $300 million - sec filing.  Full Article

TG Therapeutics says successful outcome from analysis in UNITY-CLL trial
Tuesday, 23 May 2017 07:30am EDT 

May 23 (Reuters) - TG Therapeutics Inc :TG Therapeutics Inc. announces successful outcome from pre-planned interim analysis by independent DSMB in the UNITY-CLL Phase 3 trial.TG Therapeutics Inc - found no safety concerns and recommended continuation of enrollment without modification in trial.Says study will now continue enrollment in a 1:1 ratio to only two combination arms.Says given current rate of enrollment, we are now targeting complete enrollment by year end.Says expect to report pivotal overall response rate (orr) data in Q3 of 2018.Says DSMB recommended company cease enrollment into single agent arms.  Full Article

TG Therapeutics Inc's qtrly loss per share $0.52
Friday, 5 May 2017 07:30am EDT 

May 5 (Reuters) - TG Therapeutics Inc : :TG Therapeutics Inc provides business update and reports first quarter 2017 financial results.Qtrly license revenue $38.1 million versus $38.1 million.Qtrly loss per share $0.52.TG Therapeutics - cash, cash equivalents, investment securities, and interest receivable will be sufficient to fund planned operations through 2018.TG Therapeutics -cash,cash equivalents,investment securities, interest receivable $109.5 million as of March 31 to be sufficient to fund planned operations through 2018.  Full Article

TG Therapeutics posts qtrly loss per share of $0.52
Friday, 5 May 2017 07:30am EDT 

May 5 (Reuters) - TG Therapeutics Inc ::TG Therapeutics Inc provides business update and reports first quarter 2017 financial results.Qtrly license revenue $38,095 versus $38,095.Cash, cash equivalents, investment securities, interest receivable $109.5 million as of March 31 to be sufficient to fund planned operations through 2018.Qtrly loss per share $0.52.Cash, cash equivalents, investment securities, and interest receivable will be sufficient to fund planned operations through 2018.  Full Article

BRIEF-TG Therapeutics announces completion of target enrollment

* TG Therapeutics announces completion of target enrollment in the unity-CLL phase 3 trial